Laboratory mice with pancreatic cancer that were treated with cannabidiol (CBD) in conjunction with chemotherapy lived as much as three times longer than those treated with chemotherapy alone, according to a new study released Monday.
In patients with exocrine pancreatic cancer, the most common type, the five-year survival rate when diagnosed at stage 1A is only about 14 percent. For patients diagnosed at Stage 4, that number drops to 1 percent. Survival rates for other forms of the disease are slightly higher.
Studies have shown that CBD could have potential as a therapy for cancer of the brain, bladder, breast, endocrine system, lungs, prostate, and skin as well as leukemia and Kaposi sarcoma.
See the full article at High Times